drugset / Trial / NCT00904839
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate PFS rate at 9 months of BIBF 1120 in combination with mFolfox6 compared with mFolfox6 combined to bevacizumab in first line patients with metastatic colorectal cancer.
Timeline
- Start
- 2009-05
- Primary completion
- 2012-01
- Completion
- 2012-01
Outcome
Missed primary endpoint
registry Difference -8.1 (95% CI -27.8 to 11.5); Kaplan-Meier NCT00904839 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 100 mg/Kg solution , IV infusion | Unknown | 100 mg/kg | Intravenous |
| Comparator | Nintedanib | Small molecule | 100 mg | — |
| Comparator | Nintedanib | Small molecule | 150 mg | — |